澳洲特大號外 美國公司宣佈人類已經攻克癌症

在澳大利亚医疗保健




- 6park:


美國公司宣佈人類已經攻克癌症

合成的雙鏈RNA進入肝細胞後,人體內的RNAi機制便會摧毀合成的RNA和任何與之匹配的、與腫瘤生長相關的信使RNA,阻止蛋白質的繼續產生,從而使腫瘤停止生長....
據美國媒體報導,美國阿爾尼拉姆生物技術公司日前宣佈他們找到了一種能夠治癒所有癌症的新型藥物,首批接受臨床試驗的19名晚期肝癌患者病情都有較大好轉。不僅如此,該公司稱,假以時日,這種藥物甚至有可能治癒一切疾病。

首批患者反應良好  


今年4月,19名接受化療但沒有好轉的肝癌病人開始服用這種名為ALN-VSP的新型藥物。服用第一劑後的數周內,藥物就已經很明顯地開始阻止腫瘤產生自身生長需要的蛋白質。
   到今年6月,阿爾尼拉姆公司稱,通過“喚醒”人體自身的一種很少使用的免疫防禦系統,ALN-VSP成功切斷肝癌患者體內腫瘤62%的血流量。在治療肝癌時,傳統藥物一般使用消除致病蛋白質的方法,而ALN-VSP則通過核糖核酸干擾(RNAi)療法直接阻止細胞生成致病蛋白質。

喚醒人體自身防禦機制

科學家在研究中還發現核糖核酸(RNA)和去氧核糖核酸(DNA)之間一個奇妙的聯繫———如果說DNA對蛋白質來說是一張圖紙,那麼RNA就是能夠下達指令的建築商。RNA把DNA上的基因複製成單鏈的信使RNA,再由它向細胞傳遞資訊繼而產生蛋白質。
   1998年,科學家發現了核糖核酸干擾(RNAi)機制,原始生物就利用這個系統來甄別和摧毀病毒雙鏈RNA和病毒信使RNA。研究人員發現,將一小段雙鏈RNA引入細胞即能觸發這一埋藏在人體內的古老機制,使RNAi再次發揮停止生產特定蛋白質的功效。從這一角度看,可以說RNAi具有治癒包括癌症在內的許多疾病的能力,這些疾病的特點一般都是由病變細胞產生過量的常見蛋白質所致。從理論上說,操控RNAi來殺死蛋白質並不難。比方說,ALN-VSP內就含有合成的雙鏈RNA,它與肝臟腫瘤用於編碼兩種蛋白質的信使RNA相匹配,那兩種蛋白質分別是促進腫瘤血管生長的血管內皮生長因數(VEGF)和加速腫瘤細胞快速分裂的紡錘體驅動蛋白(KSP)。
合成的雙鏈RNA進入肝細胞後,人體內的RNAi機制便會摧毀合成的RNA和任何與之匹配的、與腫瘤生長相關的信使RNA,阻止蛋白質的繼續產生,從而使腫瘤停止生長。

有望“包治百病”

   除了在癌症領域的應用,這項能攻擊單個基因的技術還在其它醫學領域掀起一陣RNAi療法旋風。目前,阿爾尼拉姆公司已經將這種療法用於亨廷頓氏舞蹈症、視網膜黃斑變性、肌肉萎縮和愛滋病等疾病的研究。

核磁共振掃描顯示,使用ALN-VSP療法後,肝臟腫瘤中的血流量明顯減少
加利福尼亞州知名分子遺傳學家約翰・羅西稱,RNAi療法有望在兩年內成熟。由於首批試驗效果相當好,ALN-VSP有望成為首批基於RNAi理論而推向市場的藥物。羅西表示:“我認為RNAi療法對所有的病都有效。”

评论
太好了,举天同庆啊!!!!

评论
好消息

评论
不是愚人节?

评论
应该是真的,只是在2012年,还是很有希望:

ALN-VSP: Liver Cancers
Alnylam has advanced its RNAi therapeutic, ALN-VSP, into the clinic for the treatment of liver cancers and potentially other solid tumors with liver involvement.

ALN-VSP targets two key genes each involved in the disease pathway of liver cancer: kinesin spindle protein, or KSP is involved in cancer proliferation, and vascular endothelial growth factor, or VEGF, is involved in the growth of new blood vessels that feed tumors. We believe that a dual-target approach in cancer increases the potential for a significant therapeutic benefit.

In April 2009, Phase I clinical trials were initiated for ALN-VSP. Results of this trial were presented at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting early June 2011. ALN-VSP is Alnylam's first systemic RNAi program and the Phase I trial results represent an important milestone in the advancement of RNAi therapeutics. Data demonstrate for the first time both clinical activity and RNAi mechanism for an RNAi therapeutic.

The Phase I study showed that ALN-VSP was generally well tolerated. ALN-VSP was administered to 41 patients at doses ranging from 0.1 to 1.5 mg/kg; a total of 209 doses have been administered, with a range of 1 to 28 doses per patient. Based the safety data, the recommended dose for advancement of ALN-VSP into Phase II studies is 1.0 mg/kg. In this study, 29 tumor biopsies were obtained voluntarily from 15 patients across multiple dose levels (from 0.4 to 1.5 mg/kg) using a CT-guided procedure; these included hepatic (liver) tumor biopsies from 11 patients and extra-hepatic tumor biopsies from four patients. The two siRNAs targeting VEGF and KSP that comprise ALN-VSP were detected in nearly all of the biopsy samples evaluable for drug levels at siRNA concentrations ranging from 0.3 to 142 ng/g tissue. These levels of siRNA are pharmacologically relevant since pre-clinical studies have shown that siRNA tissue levels of 1 ng/g are associated with 50% target gene silencing (Landesman et al., Silence, 1:16, 2010).

In June 2012, results from our Phase I extension study were presented at the ASCO Annual Meeting. These data include safety and tolerability of multiple doses of ALN-VSP, as well as evidence for anti-tumor activity in this very advanced, heavily pre-treated cancer patient population. Multiple patients achieved stable disease or better, including a patient with endometrial cancer metastatic to the liver who achieved a complete response. Results from the extension study also give us increased confidence in long-term chronic dosing with RNAi therapeutics delivered via LNPs, as patients have received drug twice a month for up to nearly two years, and approximately 11 months on average. In this study, chronic dosing of up to 23 months with ALN-VSP was found to be generally safe and well tolerated.

The drug is formulated using a first generation lipid nanoparticle developed by Tekmira Pharmaceuticals Corporation. The ALN-VSP program is partnered with Ascletis for HCC in China, and Alnylam will retain all rights in the rest of the world.

评论
惨了. I am the lengend 要来了.

评论
真的假的?

评论
应该是真的,只是在2012年,还是很有希望:

ALN-VSP: Liver Cancers
Alnylam has advanced its RNAi therapeutic, ALN-VSP, into the clinic for the treatment of liver cancers and potentially other solid tumors with liver involvement.

ALN-VSP targets two key genes each involved in the disease pathway of liver cancer: kinesin spindle protein, or KSP is involved in cancer proliferation, and vascular endothelial growth factor, or VEGF, is involved in the growth of new blood vessels that feed tumors. We believe that a dual-target approach in cancer increases the potential for a significant therapeutic benefit.

In April 2009, Phase I clinical trials were initiated for ALN-VSP. Results of this trial were presented at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting early June 2011. ALN-VSP is Alnylam's first systemic RNAi program and the Phase I trial results represent an important milestone in the advancement of RNAi therapeutics. Data demonstrate for the first time both clinical activity and RNAi mechanism for an RNAi therapeutic.

The Phase I study showed that ALN-VSP was generally well tolerated. ALN-VSP was administered to 41 patients at doses ranging from 0.1 to 1.5 mg/kg; a total of 209 doses have been administered, with a range of 1 to 28 doses per patient. Based the safety data, the recommended dose for advancement of ALN-VSP into Phase II studies is 1.0 mg/kg. In this study, 29 tumor biopsies were obtained voluntarily from 15 patients across multiple dose levels (from 0.4 to 1.5 mg/kg) using a CT-guided procedure; these included hepatic (liver) tumor biopsies from 11 patients and extra-hepatic tumor biopsies from four patients. The two siRNAs targeting VEGF and KSP that comprise ALN-VSP were detected in nearly all of the biopsy samples evaluable for drug levels at siRNA concentrations ranging from 0.3 to 142 ng/g tissue. These levels of siRNA are pharmacologically relevant since pre-clinical studies have shown that siRNA tissue levels of 1 ng/g are associated with 50% target gene silencing (Landesman et al., Silence, 1:16, 2010).

In June 2012, results from our Phase I extension study were presented at the ASCO Annual Meeting. These data include safety and tolerability of multiple doses of ALN-VSP, as well as evidence for anti-tumor activity in this very advanced, heavily pre-treated cancer patient population. Multiple patients achieved stable disease or better, including a patient with endometrial cancer metastatic to the liver who achieved a complete response. Results from the extension study also give us increased confidence in long-term chronic dosing with RNAi therapeutics delivered via LNPs, as patients have received drug twice a month for up to nearly two years, and approximately 11 months on average. In this study, chronic dosing of up to 23 months with ALN-VSP was found to be generally safe and well tolerated.

The drug is formulated using a first generation lipid nanoparticle developed by Tekmira Pharmaceuticals Corporation. The ALN-VSP program is partnered with Ascletis for HCC in China, and Alnylam will retain all rights in the rest of the world.

评论
治愈不大可能,对某种癌症有疗效倒有可能

评论
真是好消息啊

评论
希望药品尽快推出市场

评论
此次人可以长生不老了

评论
连着3次去看,是不是在大千里,确认不是!  高兴

评论
大V

评论
期待

评论


评论
我阿姨刚诊断出是肺癌,希望药品快点推出吧

评论


评论
如果是真的就太好了

评论
如果艾滋病攻克了,人类岂不是可以放心乱搞不带套了?

评论
地球要承受不了了,像月球出发吧。

评论
科学家好厉害啊

评论
如果是真的,应该可以得诺贝尔医学奖了吧~




评论
10年就有新闻了,不知现在研究进展如何

评论
那以后还有人死亡吗?

评论


评论
不大相信。按照能量守恒定律或者热量或者其他定律来说,如果没有癌症,艾滋之类的疾病,人类会更加肆无忌惮的对地球,对环境破坏,更早灭亡。


评论
今天都是大新闻,开车抢银行的,李亚鹏王菲离婚的,攻克癌症的.....
凡是必有联系,仔细想想有无内在联系....

评论

今天十三号 星期五。。

评论
Hope it is the true drug.
澳洲中文论坛热点
悉尼部份城铁将封闭一年,华人区受影响!只能乘巴士(组图)
据《逐日电讯报》报导,从明年年中开始,因为从Bankstown和Sydenham的城铁将因Metro South West革新名目而
联邦政客们具有多少房产?
据本月早些时分报导,绿党副首领、参议员Mehreen Faruqi已获准在Port Macquarie联系其房产并建造三栋投资联

医疗,保健,保险,澳洲华人,澳大利亚论坛

医疗保健

关于second opinion

澳大利亚老丈人十几年一直看一个主治医生,他在他的领域是精英,现在因为一些原因想找其他医生问问,但又不想让现在的医生知道,这个能办到吗? 评论 3rd opinion: yes 评论 怎么做到的 评论 ...

医疗保健

有人知道怎么买到CBD oil吗

澳大利亚最近睡眠不是很好,吃了一段时间安眠药感觉剂量越吃越大,有在日本的朋友说cbd oil不错,可以促进睡眠而且没什么副作用。我咨询了gp他们说得找有资格的人才能给开,也有人说成人 ...

医疗保健

亲历急诊室

澳大利亚最近一周左胸部不适,今天下午感觉重了,每隔十分八分就有一下刀割似的感觉。 前几天因为这个去看过GP,GP给我说如果胸疼直接去看急诊。 今天我就去了。走完登记流程,坐在急诊 ...

医疗保健

二大二小,悉尼求买哪种私人保险

澳大利亚不知道哪家保险性价比高?全家的,求推荐 评论 自己顶 评论 私人保险都差不多的,可以看看下面这个比较: https://www.choice.com.au/money/insurance/health/articles/medibank-bupa-hcf-hbf-nib-compared 大致 ...

医疗保健

雀巢力源素® 2.0 / Resource 2.0

澳大利亚请问有了解这款营养饮料的么? 平时做营养补充有什么需要注么? 一般在哪里购买比较好? 谢谢 评论 有病吃药,没病吃饭,不相信保健品的路过帮顶 评论 提醒一下,这东西是给病人 ...

医疗保健

经颈静脉肝内门体分流术 (TIPS)

澳大利亚因为肝硬化引起肝腹水,和门静脉系统高压,最近一次的并发症是胃出血,不太多,也不少,医生说有1-200cc, 并建议做静脉分流术,当然经过医生解释以后,道理也懂,静脉引流以后可 ...

医疗保健

孩子锻炼不小心指甲被砸断了

澳大利亚无名指的骨头也断了一点,被送去急诊,没有值班手术的医生,专门还得手部的医生,今天早上去了,那个傻逼医生居然排满了,预约明天。断的那块肉还在冰箱。医者仁心,狗屁啊, ...

医疗保健

请问如何去公立医院做白内障手术

澳大利亚是看GP直接推荐去公立医院的眼科还是推荐到眼科的specialist那儿,但是要求这个specialist能在公立医院做手术呢? 评论 你可先到验光师那里检查,如果达到做手术指征,他会开推荐信给 ...

医疗保健

孩子看验眼师Medicare 一年能报销几次?

澳大利亚以前是一年一次看的,现在验光师叫我们6个月就去复查近视情况。我问了opsm 说是如果回去他们店Medicare 能够报销,但是如果带她去别的店就不清楚了。那我如果对她眼睛度数有疑问, ...

医疗保健

胆管癌治疗方案-想听听大家的看法

澳大利亚爸爸今年75周岁,最近不幸诊断出恶性程度很高的胆管癌(肝内) 。已经在国内某大医院做过切除手术。大约是中晚期。 他是例行体检检查出来的,当时没有任何症状。手术后目前的状 ...

医疗保健

没有medicare在澳洲怎么做CT angiogram

澳大利亚妈妈一直胆固醇有点高, 最近做B超说心脏血管有轻度斑块,GP建议做个CT心脏血管造影。 开了个royal north shore private hostpital的CT 单子,但是打电话过去说要专科refer才可以做的,感到很奇 ...

医疗保健

求推荐burwood附近的JP医生

澳大利亚刚刚搬到concord居住,不知道附近有没有好的会讲中文的JP医生或诊所,另外这边有没有华人微信群可以加入,非常想加入这边的华人群体。了解当地的更多消息。 评论 是医生又是太平绅 ...

医疗保健

PR回国一年,Medicare card ?

澳大利亚爸妈是这里PR,要回中国1年多,他们下次再回澳洲,Medicare card 是不是要重新申请?听说离境超过一年就自动停了?谢谢! 评论 no 评论 没有这说法吗?之前我也是听朋友说,所以想来问 ...

医疗保健

没有电脑/手机的时代,有飞蚊症吗?

澳大利亚还有人记得吗?在电脑,智能手机还没有占据大家的生活的时代,有飞蚊症吗? 评论 当然有。现年轻化而已。 评论 那时候一般多大年龄才会有飞蚊症啊 评论 40-50 评论 我上幼儿园的时 ...

医疗保健

求推荐帮助睡眠的保健品

澳大利亚非处方的。毕竟觉得处方药的安眠药对身体伤害较大。 大家有推荐保健品类的助眠药?澳洲的,日本的,美国的,中国的都行。 人到中年,上有老,下有小,工作压力,还贷压力,,, ...

医疗保健

中药害死的人是不是比治好的多?

澳大利亚王局大战中药,揭露同仁堂中药致使数十万人罹患尿毒症: 这些年同仁堂卖过的“毒药”!|中药|仁丹|朱砂|汞超标|龙胆泻肝丸|王局拍案20240416 视频链接如下: https://www.youtu ...